Health Secretary Robert F. Kennedy Jr. is preparing a nationwide initiative to investigate suspected vaccine injuries through a dedicated NIH research clinic, expanded scientific studies and a proposed reimbursement system designed to encourage physicians to document serious adverse reactions.
By yourNEWS Media Newsroom
Health and Human Services Secretary Robert F. Kennedy Jr. is moving forward with a federal initiative to investigate suspected vaccine injuries, including the establishment of a specialized research clinic at the National Institutes of Health and a proposal to compensate physicians for reporting serious adverse events following vaccination.
The initiative represents an effort to expand the federal government’s investigation of possible vaccine-related medical complications, including conditions that patients believe have received insufficient attention from researchers and health officials.
Details emerged following an unannounced visit by Kennedy and senior administration officials to the NIH campus in Bethesda, Maryland, earlier this week, where they met with patients reporting persistent medical problems they attribute to vaccinations.
According to The New York Times’ Oct. 7 investigation, several people familiar with the initiative described plans for a research clinic at the NIH Clinical Center, additional studies examining possible vaccine-related conditions and a new medical billing code that would reimburse doctors for submitting reports of serious suspected side effects.
The proposals could substantially change how federal agencies collect information about adverse events and how researchers investigate patients who experience unusual or persistent symptoms after vaccination.
The project was previously described by Bloomberg Law, which reported details of Kennedy’s NIH visit on Monday, Oct. 5. Kennedy attended a ribbon-cutting ceremony for a clinic intended to study and care for patients reporting vaccine injuries, according to people familiar with the event.
The administration has not yet publicly released a complete implementation plan, including the program’s total funding, eligibility requirements for participating patients or the timetable for expanding research beyond Bethesda.
The Department of Health and Human Services did not respond to the Times’ request for comment, while a spokesperson for NIH Director Dr. Jay Bhattacharya declined to discuss the initiative.
Kennedy’s visit to the NIH facility marked his first trip to the campus as health secretary and brought together several senior federal officials responsible for health research, medical regulation and public insurance programs.
Among those accompanying him were Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz, Centers for Disease Control and Prevention Director Dr. Erica Schwartz and acting Food and Drug Administration Commissioner Kyle Diamantas.
Their participation reflects the potential involvement of multiple federal health agencies in an initiative that could encompass clinical research, medical reporting procedures, regulatory oversight and reimbursement policy.
A central component of the proposal involves creating a dedicated setting where medical professionals can examine patients who report significant health problems after vaccination.
The NIH Clinical Center, the federal government’s principal hospital for clinical research, would provide an environment for evaluating complex cases and investigating possible biological mechanisms associated with reported symptoms.
Researchers could examine patients’ medical histories, neurological symptoms, immune responses and other clinical findings while seeking to determine whether a particular condition is causally related to vaccination or has another explanation.
Such investigations are especially important because medical problems occurring after vaccination are not necessarily caused by the vaccine itself.
Millions of Americans receive vaccines each year, making it inevitable that some recipients will develop unrelated illnesses or symptoms shortly afterward. Establishing causation requires careful evaluation of timing, underlying medical conditions, comparison groups and biological evidence.
The new initiative is expected to emphasize that distinction through more extensive research and improved data collection.
One proposed change would provide physicians with financial reimbursement for documenting serious suspected vaccine adverse events.
Under the plan described by the Times, federal officials are considering a new medical billing code that would allow doctors to receive payment for submitting reports of potentially significant vaccine reactions.
The proposal could address a longstanding practical concern about the time required to document suspected adverse events, particularly when physicians must review medical records and provide detailed information beyond routine patient care.
The United States already operates the Vaccine Adverse Event Reporting System, commonly known as VAERS, which is jointly managed by the CDC and FDA.
The system accepts reports from medical professionals, vaccine manufacturers and members of the public concerning medical problems occurring after vaccination.
VAERS is designed to detect potential safety signals that warrant further investigation. Reports submitted to the system do not establish that a vaccine caused the medical condition described.
Federal researchers use additional monitoring systems, clinical investigations and epidemiological studies to determine whether an apparent association represents a genuine adverse reaction.
Reimbursing physicians for reporting serious events could increase participation in surveillance efforts and improve the completeness of submitted medical information.
However, the administration has not released the proposed billing code’s reimbursement amount, qualifying criteria or procedures for determining which reports would be eligible.
Those details would influence how the program operates and whether the additional reports meaningfully strengthen the federal government’s ability to identify rare complications.
The NIH initiative also builds on research priorities that federal officials outlined earlier this year.
On June 3, the agency published two highlighted research topics addressing vaccine safety, long-term health outcomes and biological mechanisms.
One NIH research announcement focused on vaccination and health outcomes across the lifespan, encouraging scientists to conduct large-scale epidemiological investigations examining both beneficial and potentially harmful long-term effects.
The agency identified opportunities to improve study designs, data sources and analytical methods used to assess outcomes following immunization.
The initiative calls for investigations that can account for differences in vaccination histories, medical conditions, demographic characteristics and other factors influencing health over time.
Such research could help distinguish vaccine-related risks from unrelated conditions while also providing additional evidence about the protective benefits of immunization.
A separate NIH research priority involving clinical studies and human-based models encouraged investigations into the biological processes underlying vaccine effectiveness, safety and susceptibility to adverse events.
The announcement identified limitations in traditional animal models, particularly when attempting to understand human immune responses and the biological pathways that may contribute to uncommon medical complications.
Researchers were encouraged to use clinical studies and other human-based approaches to examine individual differences in vaccine responses.
Both notices remain active research priorities through June 2028.
Although the announcements do not establish that specific vaccine injuries are more common than previously understood, they provide a framework for additional research into questions that federal health agencies have identified as deserving scientific examination.
The agency’s emphasis on improved data collection could also support efforts to investigate patients whose symptoms do not fit established diagnostic categories.
Among those who participated in Kennedy’s meeting at NIH was Brianne Dressen, a former preschool teacher from Utah who has publicly described developing severe neurological symptoms after participating in a clinical trial of AstraZeneca’s COVID-19 vaccine.
Dressen received the experimental vaccine in November 2020, during the early stages of clinical testing for coronavirus vaccines.
She told the Times that she began experiencing tingling in her arms and legs within approximately an hour of receiving the injection.
According to her account, the symptoms subsequently progressed to significant pain and other neurological problems that interfered with her ability to perform ordinary activities.
Dressen said her condition became so severe that she temporarily required a wheelchair and lost approximately 40 pounds.
After seeking medical assistance, she contacted the NIH Clinical Center in January 2021.
Dressen said physicians at the facility diagnosed her with “post-vaccine neuropathy,” a term describing nerve-related symptoms considered to have developed following vaccination.
Her account illustrates the type of complex medical history that researchers may examine under the proposed initiative, although the diagnosis and reported timing do not independently establish the precise biological cause of all her symptoms.
Dressen subsequently founded React19, an organization representing people who report persistent medical problems following COVID-19 vaccination and advocating for additional research, medical recognition and patient support.
The organization has also called for greater investigation into the potential overlap between symptoms reported after vaccination and those associated with long COVID.
Both conditions have prompted scientific interest because some patients report neurological complications, fatigue, pain, cognitive difficulties and other symptoms that can persist for extended periods.
Researchers continue to investigate the biological mechanisms underlying these conditions, including possible immune system dysfunction and inflammation.
The NIH has separately studied neurological symptoms associated with long COVID, including the possibility that abnormal immune responses contribute to persistent illness in some patients.
A June 2026 NIH research summary described experimental findings suggesting that certain antibodies may contribute to nervous system symptoms in people experiencing long COVID.
Those findings concern the effects of SARS-CoV-2 infection and do not establish that vaccination produces the same medical condition or operates through identical biological mechanisms.
Dressen characterized Kennedy’s initiative as a significant development for patients who have spent years seeking additional federal attention.
“This is the first time there’s been anything even remotely official,” she told the Times.
Her remarks reflect the frustration expressed by some patients who believe their experiences have not received sufficient clinical investigation or acknowledgment.
Kennedy has made vaccine safety a central issue throughout his public career and during his tenure as health secretary.
Before entering the Trump administration, he repeatedly questioned the safety of vaccines, criticized aspects of federal vaccine oversight and called for further investigation into possible connections between immunizations and chronic health conditions.
He has also raised concerns about ingredients used in certain vaccines, including aluminum-containing compounds that function as adjuvants to help strengthen immune responses.
Those positions have drawn substantial criticism from medical researchers and public health organizations, which point to extensive scientific evidence supporting the safety and effectiveness of routinely recommended vaccines.
Multiple large studies have found no causal relationship between childhood vaccines and autism, and existing research does not support the claim that routine immunizations are responsible for a broad increase in chronic diseases.
Serious adverse reactions to vaccines can occur, however, and recognized complications vary according to the specific vaccine, medical condition and patient population.
Established examples include rare severe allergic reactions and certain vaccine-associated inflammatory conditions.
Myocarditis and pericarditis have been identified as uncommon adverse events following some mRNA COVID-19 vaccines, particularly among adolescent and young adult males.
Other vaccine products have been associated with rare but serious complications, including specific neurological and blood-clotting disorders.
Federal health agencies have previously responded to confirmed safety signals by modifying recommendations, updating product warnings or changing how certain vaccines are used.
These findings demonstrate the importance of continuing safety surveillance even after vaccines receive regulatory authorization.
At the same time, public health authorities maintain that the benefits of recommended vaccination substantially outweigh the risks for most people, particularly when the diseases being prevented can cause severe illness, hospitalization, disability or death.
The proposed federal research initiative would enter an established field of vaccine safety science rather than create the first government system dedicated to monitoring adverse events.
Its potential significance lies in expanding clinical investigations and creating new mechanisms for obtaining detailed information about serious suspected reactions.
Some medical researchers have welcomed the possibility of additional research while emphasizing that any federally supported program must follow rigorous scientific standards.
Dr. Helen Chu, an infectious disease specialist at the University of Washington and former member of the CDC’s Advisory Committee on Immunization Practices, told the Times that adverse events deserve more sustained scientific attention.
“I do think that we do need to take these adverse events more seriously, and I think that we need to build that into how we fund scientific research in the future,” Chu said.
Her comments reflect support for improving the evidence available to patients, clinicians and policymakers rather than assuming that every reported medical problem is vaccine-related.
Dr. Daniel Salmon, director of the Institute for Vaccine Safety at the Johns Hopkins Bloomberg School of Public Health, expressed a similar position.
“More research in vaccine safety would be very helpful,” Salmon told the Times, adding, “It needs to be rigorous science.”
That requirement is particularly important when studying rare medical outcomes, since small numbers of cases, incomplete reporting and differences in underlying health conditions can make it difficult to identify causal relationships.
Researchers must also account for the possibility that some patients develop symptoms after vaccination for reasons unrelated to the vaccine itself.
Well-designed studies typically use comparison groups, validated medical diagnoses and appropriate statistical methods to distinguish genuine safety signals from coincidental associations.
Independent scientific review and transparent publication of findings can further strengthen confidence in the results.
The proposed program also arrives during a period of significant disagreement over federal vaccine policy.
Kennedy has changed the membership of the CDC’s vaccine advisory committee and pursued revisions to national immunization recommendations, actions that have faced criticism and legal challenges from medical organizations.
On Oct. 6, a federal appeals court considered the administration’s challenge to a lower court order restricting Kennedy’s appointments to the Advisory Committee on Immunization Practices.
According to Reuters’ coverage of the hearing, the dispute involves whether the appointments complied with federal requirements governing the composition and qualifications of advisory panels.
The controversy underscores broader disagreements over how federal health officials should evaluate vaccine evidence and how much weight should be given to concerns about rare adverse events.
Kennedy’s vaccine injury initiative is being developed as public health agencies also confront renewed outbreaks of preventable infectious diseases.
Measles cases have increased in several parts of the United States, including communities with low vaccination rates.
On Oct. 7, Kennedy offered federal assistance to New York Gov. Kathy Hochul as the state responded to a growing measles outbreak.
The reported federal response included coordination with CDC Director Schwartz following New York’s declaration of a statewide disaster emergency intended to improve vaccine access and address the spread of the disease.
The developments illustrate the separate responsibilities facing federal health agencies: maintaining effective vaccination programs to prevent infectious diseases while investigating possible medical complications associated with immunization.
Federal law already provides mechanisms for compensation in certain cases involving established vaccine injuries.
The National Vaccine Injury Compensation Program, administered through the Health Resources and Services Administration and the U.S. Court of Federal Claims, allows eligible individuals to seek compensation for injuries associated with covered vaccines.
The program evaluates petitions using medical evidence and legal standards, including a table identifying certain conditions that may qualify for compensation when they occur within specified periods following vaccination.
A September 2026 Federal Register notice described the continuing process for reviewing vaccine injury petitions and determining eligibility for compensation.
The newly discussed research initiative is separate from that compensation system.
Its proposed physician reimbursement mechanism would pay for reporting suspected adverse events, not automatically compensate patients or establish that reported injuries were caused by vaccines.
Whether the administration intends to pursue additional changes to existing compensation programs remains unclear.
Similarly, the proposed NIH clinic would be expected to investigate medical conditions and possible biological mechanisms, but details concerning treatment protocols and long-term patient services have not been publicly established.
The initiative’s scope could expand if other research institutions across the country are invited to participate.
A broader network might allow scientists to study larger groups of patients, compare findings across clinical centers and evaluate rare conditions that would be difficult to investigate at a single hospital.
Such coordination could also improve the quality of information available to physicians treating patients with unusual or persistent symptoms.
However, the effectiveness of the program will depend on its funding, research design, leadership, access to reliable medical records and willingness to publish findings regardless of whether they support or contradict previously expressed views about vaccine safety.
For patients seeking answers, the proposed federal effort creates the possibility of additional clinical evaluations and scientific attention.
For vaccine safety researchers, it offers an opportunity to improve the detection and investigation of uncommon medical complications while examining the long-term health effects of immunization.
The administration has not yet disclosed when the proposed physician reimbursement system might begin, how many patients the NIH clinic would accept or which medical conditions would receive priority.
Until those details are released, the initiative remains an emerging federal program whose ultimate scope and effectiveness are uncertain.
Kennedy’s visit to NIH and the agency’s published research priorities nevertheless indicate that vaccine injury investigations are becoming a more prominent component of federal health policy.
The central question will be whether the new research produces reliable evidence that improves patient care, strengthens vaccine safety monitoring and provides clearer answers about suspected adverse reactions without undermining established scientific findings concerning the benefits of immunization.
Original article
Comments